What is HC Wainwright’s Forecast for CTMX FY2025 Earnings?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Investment analysts at HC Wainwright decreased their FY2025 earnings estimates for CytomX Therapeutics in a research note issued to investors on Tuesday, November 11th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per share of ($0.03) for the year, down from their prior estimate of $0.17. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.34) EPS.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The company had revenue of $5.96 million for the quarter, compared to analyst estimates of $11.50 million. CytomX Therapeutics had a net margin of 34.04% and a return on equity of 158.70%.

A number of other brokerages have also recently commented on CTMX. Wall Street Zen cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Oppenheimer initiated coverage on shares of CytomX Therapeutics in a research report on Thursday, July 31st. They issued an “outperform” rating and a $7.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $6.00 price objective on shares of CytomX Therapeutics in a research report on Friday, November 7th. Weiss Ratings upgraded CytomX Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald began coverage on CytomX Therapeutics in a research note on Monday, September 22nd. They issued an “overweight” rating and a $6.00 price objective for the company. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.67.

CytomX Therapeutics Stock Performance

Shares of NASDAQ CTMX traded down $0.28 during mid-day trading on Thursday, hitting $3.96. 1,269,286 shares of the stock were exchanged, compared to its average volume of 3,383,497. The stock’s fifty day simple moving average is $3.07 and its two-hundred day simple moving average is $2.46. CytomX Therapeutics has a twelve month low of $0.40 and a twelve month high of $4.62. The company has a market cap of $670.12 million, a P/E ratio of 7.04 and a beta of 2.29.

Institutional Investors Weigh In On CytomX Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC bought a new position in CytomX Therapeutics during the 3rd quarter worth about $25,000. Miller Financial Services LLC lifted its stake in CytomX Therapeutics by 104.0% during the first quarter. Miller Financial Services LLC now owns 51,000 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 26,000 shares in the last quarter. Invesco Ltd. purchased a new position in CytomX Therapeutics in the second quarter worth approximately $32,000. Pursue Wealth Partners LLC purchased a new stake in CytomX Therapeutics in the second quarter valued at approximately $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of CytomX Therapeutics during the third quarter worth about $34,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.